Genomic Health, Inc. (NASDAQ:GHDX) has received an average recommendation of “Hold” from the eleven analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $32.67.

Several research firms have commented on GHDX. Canaccord Genuity reaffirmed a “buy” rating and issued a $39.00 target price on shares of Genomic Health in a research note on Wednesday, November 15th. ValuEngine cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Jefferies Group reaffirmed a “hold” rating and issued a $34.00 target price on shares of Genomic Health in a research note on Friday, October 20th. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. Finally, Cowen reaffirmed a “hold” rating and issued a $34.00 target price on shares of Genomic Health in a research note on Friday, September 1st.

Shares of Genomic Health (GHDX) opened at $30.10 on Monday. Genomic Health has a 12 month low of $26.37 and a 12 month high of $34.02.

In other Genomic Health news, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $31.86, for a total value of $159,300.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,379 shares of company stock worth $676,131. 46.20% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Wetherby Asset Management Inc. boosted its holdings in shares of Genomic Health by 3.7% in the 2nd quarter. Wetherby Asset Management Inc. now owns 8,912 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 317 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Genomic Health by 5.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after purchasing an additional 441 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Genomic Health by 3.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock valued at $516,000 after acquiring an additional 520 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Genomic Health by 11.4% during the 2nd quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock valued at $226,000 after acquiring an additional 710 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Genomic Health by 0.9% during the 2nd quarter. American Century Companies Inc. now owns 127,294 shares of the medical research company’s stock valued at $4,143,000 after acquiring an additional 1,092 shares in the last quarter. Institutional investors own 89.67% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/genomic-health-inc-ghdx-given-average-recommendation-of-hold-by-analysts/1742201.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.